Clinical trial ARTEMIDE-01
A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non small Cell Lung Cancer (ARTEMIDE-01)(D7020C00001)
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2021-000857-23 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04995523 |
| Last update |